Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for some types of allergies. It is useful for environmental allergies, allergies to insect bites, and asthma. The treatment involves exposing people to larger and larger amounts of allergen in an attempt to change the immune system’s response. People are typically treated by giving them injections containing small amounts of the substance they are allergic to, such as pollen, animal dander, bee venom, or house dust mites. The doses are slowly increased over a period of many months so the person can become desensitized to the allergen. Tablets containing allergen extracts or allergen drops under the tongue are also options.

The global allergy immunotherapy market incorporates different types of medications and therapies for various allergic diseases. The major products in this market are subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). SCIT involves injecting allergen extracts under the skin, usually on the upper arm or thigh, while SLIT involves placing allergen extracts under the tongue. These therapies are used to treat allergies such as allergic rhinitis, asthma, conjunctivitis, food allergies, insect sting allergies, and anaphylaxis.

The global allergy immunotherapy market is estimated to be valued at US$ 1,966.74 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics

Rising Demand for Personalized Medicine: The key driver for the growth of the global allergy immunotherapy market is rising demand for personalized treatment and management of allergies. Allergies are highly variable between individuals based on several factors such as genetic predisposition, environmental exposures, and lifestyle habits. Conventional medications tend to be same for all patients with a particular type of allergy. However, allergy immunotherapy offers personalized diagnosis and treatment by understanding each patient’s unique allergen sensitivities and tailoring the immunotherapy accordingly. This offers long-term benefit and greater chance of becoming symptom-free after discontinuing the treatment.

Focus on Precision Medicine: Another important factor fueling the allergy immunotherapy market growth is increasing focus on precision medicine. Researchers are investigating ways to better understand disease mechanisms and using this insight to develop more targeted immunotherapy approaches. For example, studies are evaluating the role of specific immune cells and molecules involved in triggering allergic reactions.

Segment Analysis

The allergy immunotherapy market can be segmented based on treatment, allergy type, end-user and region. By treatment, the market is classified into sublingual immunotherapy and subcutaneous immunotherapy. The sublingual immunotherapy segment dominates the market, as it is needle-free and provides convenience of oral administration. By allergy type, the market is categorized into pollen immunotherapy, dust mite immunotherapy, cockroach immunotherapy and multiple allergens. Pollen immunotherapy currently holds the largest share, as pollen-induced allergies are highly common. By end-user, the market is divided into hospitals, ambulatory surgical centers and others. Hospitals dominate the segment due to availability of advanced treatment facilities and presence of skilled professionals.

PEST Analysis

Political: Regulations supporting reimbursement of allergy immunotherapy treatment is driving the market growth.

Economic: Rising income levels in developing nations is increasing affordability for allergy treatment. This is supporting market expansion.

Social: Growing allergy prevalence globally due to changing lifestyle and environment is boosting demand for immunotherapy.

Technological: Digital technology advancements in immunotherapy treatment delivery methods are augmenting market growth. Technologies including sublingual tablets and mobile applications are gaining popularity.

Key Takeaways

The global allergy immunotherapy market is expected to witness high growth. The global allergy immunotherapy market is estimated to be valued at US$ 1,966.74 mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023-2031.

The North America region dominates the market currently. This is attributed to factors such as rising allergy prevalence, presence ofadvanced healthcare infrastructure, and favorable reimbursement policies.

Key players operating in the allergy immunotherapy market are B. Braun Vet Care GmbH, BioMedtrix, LLC, IMEX Veterinary, Inc., Innoplant Medizintechnik GmbH, KYON AG, Orthomed (UK) Ltd., BLUESAO Co. Ltd., New Generation Devices (NGD), Johnson & Johnson, MWI Animal Health, AmerisourceBergen Corporation, Platon Japan Co., Ltd., Veterinary Orthopedic Implants, NORER Orthopedic & Dental, OC Oerlikon Management AG, Jindal Medi Surge, Inc., and Mercury Orthopedics and Design, Inc.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it